NCT01526486
- Conditions
- Adenocarcinoma, Anal Cancer, Anus Diseases, +67 more
- Locations
-
- Emory University Hospital-Winship Cancer Institute Atlanta, Georgia, United States
Clinical trial condition
Carcinoma, Merkel Cell
Explore clinical trials studying Carcinoma, Merkel Cell. Study availability and eligibility vary by location and protocol.
103 public trials
29 recruiting studies
Carcinoma, Merkel Cell trial results
NCT00346385
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bronchial Neoplasms, +38 more
- Locations
-
- University of California San Francisco San Francisco, California, United States
- Nevada Cancer Institute Las Vegas, Nevada, United States
- The Ohio State University Cancer Center and Research Institute Columbus, Ohio, United States
- Oklahoma University Oklahoma City, Oklahoma, United States
NCT00004922
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma of Unknown Primary, +21 more
- Locations
-
- Memorial Sloan-Kettering Cancer Center New York, United States
NCT00079131
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Merkel Cell, +18 more
- Locations
-
- Memorial Sloan-Kettering Cancer Center New York, United States
Completed
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
NCT00068783
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Merkel Cell, +16 more
- Locations
-
- Southwest Oncology Group San Antonio, Texas, United States
NCT00003549
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Merkel Cell, +14 more
- Locations
-
- MBCCOP - University of South Alabama Mobile, Alabama, United States
- CCOP - Greater Phoenix Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Phoenix (Hayden) Phoenix, Arizona, United States
- Veterans Affairs Medical Center - Tucson Tucson, Arizona, United States
NCT00765193
- Conditions
- Adenocarcinoma, Basal Cell Carcinoma, Carcinoma, +27 more
- Locations
-
- Medical University of Graz-Austria: Department of Dermatology Graz, Austria
Active, Not Recruiting
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
NCT05078047
- Conditions
- Adenocarcinoma, Basal Cell Carcinoma, Breast Diseases, +69 more
- Locations
-
- Institut de cancérologie de l'Ouest Angers, France
- Clinique Sainte Catherine Avignon, France
- Centre Hospitalier de la Côte Basque Bayonne, France
- CHU Bordeaux - Hôpial Saint André Bordeaux, France
Active, Not Recruiting
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
NCT05947500
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Merkel Cell, +19 more
- Locations
-
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- Keck Medicine of USC Koreatown Los Angeles, California, United States
- Los Angeles General Medical Center Los Angeles, California, United States
Active, Not Recruiting
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT04616248
- Conditions
- Adenocarcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Basal Cell Carcinoma, +44 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC/Norris Comprehensive Cancer Center Los Angeles, California, United States